Reply to López-Campos : Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect.
作者信息
Lipson David A, Han MeiLan K, Wise Robert, Martinez Fernando J
机构信息
GlaxoSmithKline Collegeville, Pennsylvania.
University of Pennsylvania Philadelphia, Pennsylvania.
出版信息
Am J Respir Crit Care Med. 2021 Apr 1;203(7):928-929. doi: 10.1164/rccm.202012-4494LE.
Abstract
摘要
相似文献
1
Reply to López-Campos : Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect.回复洛佩斯 - 坎波斯：慢性阻塞性肺疾病的三联疗法试验：死亡率效应的方法学考量
Am J Respir Crit Care Med. 2021 Apr 1;203(7):928-929. doi: 10.1164/rccm.202012-4494LE.
2
Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?慢性阻塞性肺疾病的固定三联疗法与生存率。是活得更好、更久，还是两者兼得？
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1463-1464. doi: 10.1164/rccm.202003-0622ED.
3
Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?对苏伊萨的回复：IMPACT研究中的死亡率：被哮喘混淆了？
Am J Respir Crit Care Med. 2020 Sep 1;202(5):773-774. doi: 10.1164/rccm.202004-1399LE.
4
[Once daily with a powder inhaler].
MMW Fortschr Med. 2015 Jun 11;157(11):66. doi: 10.1007/s15006-015-3225-9.
5
Mortality in IMPACT: Confounded by Asthma?IMPACT研究中的死亡率：受哮喘影响而混淆？
Am J Respir Crit Care Med. 2020 Sep 1;202(5):772-773. doi: 10.1164/rccm.202004-1159LE.
6
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.FULFIL 试验：慢性阻塞性肺疾病患者的每日一次三联疗法。
Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446. doi: 10.1164/rccm.201703-0449OC.
7
Fluticasone furoate and vilanterol for COPD - authors' reply.糠酸氟替卡松和维兰特罗用于慢性阻塞性肺疾病——作者回复
Lancet Respir Med. 2013 Jul;1(5):e21-2. doi: 10.1016/S2213-2600(13)70125-5. Epub 2013 Jul 8.
8
Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.糠酸氟替卡松/乌美溴铵/维兰特罗三联疗法治疗慢性阻塞性肺疾病患者的真实临床和功能效果。
Respiration. 2021;100(2):127-134. doi: 10.1159/000512064. Epub 2020 Dec 10.
9
Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease.氟替卡松乌美溴铵维兰特罗三联治疗慢性阻塞性肺疾病。
Expert Rev Respir Med. 2018 Dec;12(12):997-1005. doi: 10.1080/17476348.2018.1548936. Epub 2018 Nov 28.
10
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.氟替卡松维兰特罗/乌美溴铵粉雾剂降低慢性阻塞性肺疾病患者全因死亡率。
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC.
本文引用的文献
1
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.氟替卡松维兰特罗/乌美溴铵粉雾剂降低慢性阻塞性肺疾病患者全因死亡率。
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC.
2
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.COPD 患者每日一次单吸入器三联与双联治疗。
N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.
Zotero 插件